PMID- 26202440
OWN - NLM
STAT- MEDLINE
DCOM- 20160413
LR  - 20221207
IS  - 1613-2246 (Electronic)
IS  - 0021-5155 (Linking)
VI  - 59
IP  - 5
DP  - 2015 Sep
TI  - Bimatoprost 0.01 % for previously treated patients with open-angle glaucoma or 
      ocular hypertension in the Korean clinical setting.
PG  - 325-34
LID - 10.1007/s10384-015-0392-2 [doi]
AB  - PURPOSE: To evaluate the occurrence of hyperemia with, and efficacy of, 
      bimatoprost 0.01 % for patients in Korea previously treated for open-angle 
      glaucoma (OAG; including normal tension glaucoma) or ocular hypertension (OHT). 
      METHODS: In this multicenter, observational study (Asia Pacific Patterns from 
      Early Access of Lumigan 0.01 % in Korea; APPEAL Korea), patients with unachieved 
      target intraocular pressure (IOP) despite previous treatment received bimatoprost 
      0.01 % daily for 12 weeks. The primary endpoint was incidence of hyperemia and 
      its severity, graded using the standard 5-point photographic scale and grouped as 
      "none to mild" and "moderate to severe". Hyperemia shifts were reported. IOP and 
      adverse events (AEs) were recorded. RESULTS: Of 800 patients 
      (intent-to-treat/safety population), 248 were switched from previous treatment to 
      bimatoprost 0.01 % monotherapy. Hyperemia shifts from baseline at weeks 6 and 12 
      were unchanged (84.8, 89.8 %), improved (4.4, 4.8 %), or worsened (10.8, 5.4 %), 
      respectively. The shift was significant at week 6 (P < 0.0001). Hyperemia did not 
      worsen significantly in patients previously receiving a prostaglandin analog or 
      prostamide (PGA/PSD). Baseline mean IOP +/- SD was 17.0 +/- 5.7 mmHg, decreasing to 
      14.6 +/- 3.8 mmHg (P < 0.0001) after 6 weeks, and to 14.7 +/- 3.6 mmHg (P < 0.0001) 
      after 12 weeks. Patients switched from PGA or PSD (excluding bimatoprost 0.03 %) 
      to bimatoprost 0.01 % experienced significant IOP reductions from baseline. 
      Treatment-related ocular AEs were reported by 37 patients, the most common being 
      hyperemia (7.3 %). CONCLUSIONS: This subanalysis of the APPEAL Korea study 
      supports use of bimatoprost 0.01 % for previously treated patients with OAG 
      (including normal tension glaucoma) or OHT who did not reach target IOP or were 
      intolerant of previous treatment.
FAU - Kook, Michael Scott
AU  - Kook MS
AD  - Department of Ophthalmology, Asan Medical Centre, 388-1 Pungnap-dong, Songpa-Gu, 
      Seoul, Korea. mskook@amc.seoul.kr.
FAU - Simonyi, Susan
AU  - Simonyi S
AD  - Allergan Singapore Pte, Ltd., Mapletree Business City, Singapore, Singapore.
FAU - Sohn, Yong Ho
AU  - Sohn YH
AD  - Kim's Eye Hospital, Seoul, Korea.
FAU - Kim, Chan Yun
AU  - Kim CY
AD  - Department of Ophthalmology, Yonsei University, College of Medicine, Seoul, 
      Korea.
FAU - Park, Ki Ho
AU  - Park KH
AD  - Department of Ophthalmology, Seoul National University Hospital, Seoul, Korea.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20150723
PL  - Japan
TA  - Jpn J Ophthalmol
JT  - Japanese journal of ophthalmology
JID - 0044652
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Ophthalmic Solutions)
RN  - QXS94885MZ (Bimatoprost)
SB  - IM
MH  - Administration, Topical
MH  - Aged
MH  - Antihypertensive Agents/*therapeutic use
MH  - Asian People
MH  - Bimatoprost/*therapeutic use
MH  - Conjunctiva/blood supply
MH  - Drug Substitution
MH  - Female
MH  - Glaucoma, Open-Angle/diagnosis/*drug therapy/physiopathology
MH  - Humans
MH  - Hyperemia/physiopathology
MH  - Intraocular Pressure/drug effects
MH  - Male
MH  - Middle Aged
MH  - Ocular Hypertension/diagnosis/*drug therapy/physiopathology
MH  - Ophthalmic Solutions
MH  - Republic of Korea
MH  - Single-Blind Method
MH  - Tonometry, Ocular
OTO - NOTNLM
OT  - Bimatoprost
OT  - Glaucoma
OT  - Hyperemia
OT  - Ocular hypertension
OT  - Prostamide
EDAT- 2015/07/24 06:00
MHDA- 2016/04/14 06:00
CRDT- 2015/07/24 06:00
PHST- 2014/11/19 00:00 [received]
PHST- 2015/05/21 00:00 [accepted]
PHST- 2015/07/24 06:00 [entrez]
PHST- 2015/07/24 06:00 [pubmed]
PHST- 2016/04/14 06:00 [medline]
AID - 10.1007/s10384-015-0392-2 [pii]
AID - 10.1007/s10384-015-0392-2 [doi]
PST - ppublish
SO  - Jpn J Ophthalmol. 2015 Sep;59(5):325-34. doi: 10.1007/s10384-015-0392-2. Epub 
      2015 Jul 23.